Early arthritis cohorts: demographics and disease characteristics
| Analysis datasets | Validation datasets | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Total | Amsterdam | Austria | ESPOIR | Manchester | Norway | REACH | Leeds | Leiden | Toronto | |
| N | 3115 | 134 | 72 | 796 | 262 | 544 | 265 | 695 | 213 | 134 |
| Mean (SD) age (years) | 51 (15) | 49 (13) | 51 (15) | 48 (13) | 54 (16) | 46 (15) | 52 (16) | 58 (14) | 57 (17) | 45 (14) |
| Sex (% female) | 66.8 | 61.2 | 63.9 | 76.6 | 67.6 | 55.7 | 62.6 | 64.5 | 66.7 | 79.9 |
| Mean (SD) duration of arthritis (months) | 4.9 (4.6) | 5.3 (3.7) | 2.7 (2.9) | 4.6 (3.7) | 7.1 (6.6) | 1.2 (1.5) | 3.7 (3.1) | 7.3 (5.0) | 5.9 (5.4) | 5.8 (3.1) |
| Mean (SD) swollen joint count (0–28) | 6.6 (6.2) | 4.3 (4.9) | 5.9 (6.1) | 7.2 (5.4) | 3.7 (4.7) | 2.8 (4.4) | 3.7 (4.1) | 10.8 (6.7) | 6.7 (5.6) | 10.1 (7.2) |
| Mean (SD) tender joint count (0–28) | 8.0 (7.7) | 5.4 (6.0) | 6.6 (7.1) | 8.4 (7.0) | 5.0 (6.6) | 3.4 (5.1) | 5.1 (5.0) | 13.3 (8.3) | 8.3 (7.2) | 11.7 (7.8) |
| Mean (SD) ESR (mm) | 32 (25) | 29 (24) | 42 (33) | 30 (25) | – | 31 (24) | 29 (23) | 39 (27) | 34 (26) | 24 (23) |
| Mean (SD) CRP (mg/l) | 26 (42) | 19 (26) | 34 (40) | 20 (30) | 17 (29) | 34 (45) | 20 (31) | 34 (60) | 26 (35) | 14 (25) |
| Mean (SD) patient global assessment (mm) | 56 (26) | – | 52 (28) | 60 (26) | – | 53 (24) | 48 (24) | 61 (25) | 49 (27) | 60 (29) |
| Mean (SD) physician global assessment (mm) | 46 (23) | – | 39 (21) | 50 (22) | – | 36 (21) | 35 (22) | 49 (22) | – | 60 (25) |
| Mean (SD) pain scores (mm) | 54 (27) | 49 (31) | 46 (28) | 55 (26) | 38 (26) | 52 (26) | – | 63 (27) | 47 (22) | 56 (28) |
| Morning stiffness (min, % ≥1 h) | 38.5 | 18.7 | 26.1 | 30.9 | 53.1 | – | 31.2 | 51.6 | 29.4 | – |
| Mean (SD) HAQ (0–3) | 1.0 (0.7) | 1.0 (0.7) | 1.0 (0.8) | 1.0 (0.7) | 0.8 (0.7) | 0.8 (0.7) | 0.8 (0.6) | 1.3 (0.7) | 1.0 (0.7) | 0.9 (0.7) |
| Anti-CCP antibodies, % positive | 29.5 | 25.0 | 50.0 | 38.6 | 19.9 | 14.2 | 19.9 | – | 35.1 | 57.4 |
| Rheumatoid factors, % positive | 42.6 | 25.6 | 42.9 | 25.4 | 35.5 | 13.3 | 24.5 | 72.7 | 43.7 | –* |
| Data on joint regions/symmetry | No | Yes | No | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| Data on feet involvement | No | Yes | No | No | No | Yes | Yes | No | Yes | Yes |
↵* Only titres available.
anti-CCP, anti-cyclic citrullinated protein; CRP, C reactive protein; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire.